• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 3. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Quaternary ammonium salts

1-(Methylamino)Propan-2-Ol Hydrochloride (CAS No. 83176-70-9): A Multifunctional Chemical Entity in Modern Drug Design

1-(methylamino)propan-2-ol hydrochloride, identified by the CAS registry number 83176-70-9, represents a versatile small molecule with significant applications in pharmaceutical research and development. This compound, featuring a branched propane skeleton with a secondary hydroxyl group at position 2 and a methylamino substituent at position 1, exists in its hydrochloride salt form to enhance solubility and stability. Recent advancements in computational chemistry and medicinal chemistry have highlighted its potential as a scaffold for designing bioactive compounds targeting diverse therapeutic areas.

Propan-2-ol structural motifs are increasingly recognized for their ability to modulate pharmacokinetic properties such as membrane permeability and metabolic stability. The methylamino group imparts basic character, enabling pH-dependent ionization profiles critical for drug delivery systems. Structural analysis via X-ray crystallography (Smith et al., 2023) revealed conformational preferences that align with binding pockets of protein targets, particularly kinases and ion channels.

Synthetic strategies for this compound have evolved significantly since its initial preparation. Traditional methods involving alkylation of amino alcohols now face competition from environmentally sustainable approaches like enzymatic catalysis reported by Lee et al. (Nature Catalysis, 2024). These advancements reduce reaction steps while achieving >95% enantiomeric excess, crucial for chiral pharmaceutical intermediates.

In neuropharmacology research, this compound's analogs demonstrate promising in vitro activity against neuroinflammatory pathways. A 2024 study published in Nature Communications showed that derivatives inhibit microglial activation through modulation of NLRP3 inflammasome activity—a mechanism linked to neurodegenerative disease progression. The methylamino propanol backbone facilitates blood-brain barrier penetration due to its optimized lipophilicity (logP = 1.8).

Clinical translational studies highlight its utility as a prodrug carrier system. When conjugated with therapeutic payloads via amide linkages, the molecule enables controlled release profiles in targeted delivery systems. Preclinical trials in rodent models demonstrated enhanced efficacy of anticancer agents when delivered through these conjugates (Journal of Controlled Release, 2024).

Safety evaluations using advanced toxicogenomics approaches have provided mechanistic insights into its safety profile. Transcriptomic analysis revealed minimal off-target effects at therapeutic concentrations (<5 mM), with no significant alterations observed in hepatic drug-metabolizing enzymes beyond expected phase I/II responses (Toxicological Sciences, 2024).

Ongoing research focuses on exploiting this compound's unique hydrogen-bonding capacity for peptide stabilization applications. Solid-phase peptide synthesis studies show improved yields when using this entity as a protecting group during Fmoc-based synthesis protocols (Angewandte Chemie, 2024).

In the realm of analytical chemistry, novel chiral stationary phases incorporating this compound's structural elements have been developed for high-resolution chromatography applications. These stationary phases enable enantiomeric separation of complex pharmaceutical intermediates under ambient conditions—a breakthrough for quality control processes.

Cross-disciplinary studies now explore its role in material science applications such as stimuli-responsive polymers and enzyme mimics. Self-assembling nanostructures incorporating this molecule exhibit pH-sensitive conformational changes useful for smart drug carriers (Advanced Materials, 2024).

The evolving understanding of this chemical entity underscores its status as a platform molecule bridging organic synthesis and biomedical innovation. Continued exploration across multiple disciplines promises further discoveries that will expand its role in addressing unmet medical needs while maintaining adherence to modern regulatory standards.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)